Compare PRCT & PTA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | PRCT | PTA |
|---|---|---|
| Founded | 2009 | 2020 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical Specialities | Trusts Except Educational Religious and Charitable |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 942.4M |
| IPO Year | 2021 | N/A |
| Metric | PRCT | PTA |
|---|---|---|
| Price | $17.56 | $16.82 |
| Analyst Decision | Hold | |
| Analyst Count | 15 | 0 |
| Target Price | ★ $22.25 | N/A |
| AVG Volume (30 Days) | ★ 1.3M | 305.9K |
| Earning Date | 11-04-2026 | 01-01-0001 |
| Dividend Yield | N/A | ★ 8.31% |
| EPS Growth | ★ 1.71 | N/A |
| EPS | ★ N/A | N/A |
| Revenue | ★ $308,054,000.00 | N/A |
| Revenue This Year | $28.32 | N/A |
| Revenue Next Year | $20.48 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 37.22 | N/A |
| 52 Week Low | $16.67 | $16.66 |
| 52 Week High | $38.11 | $20.15 |
| Indicator | PRCT | PTA |
|---|---|---|
| Relative Strength Index (RSI) | 45.00 | 34.17 |
| Support Level | $16.84 | N/A |
| Resistance Level | $29.27 | $19.59 |
| Average True Range (ATR) | 0.99 | 0.25 |
| MACD | 0.12 | -0.01 |
| Stochastic Oscillator | 35.14 | 14.95 |
PROCEPT BioRobotics Corp is a surgical robotics company focused on advancing patient care by developing transformative solutions in urology. The company develops, manufactures, and sells the AquaBeam Robotic System and HYDROS Robotic System, image-guided, surgical robotic systems for use in minimally invasive urologic surgery, with an initial focus on treating benign prostatic hyperplasia, or BPH. Geographically, the company generates a majority of its revenue from the United States and also has a presence in markets outside the U.S.
COHEN & STEERS TAX-ADV PRD SEC AND INC is a non-diversified, closed-end management statutory trust. Its main investment objective is high current income, and the Fund's secondary investment objective is capital appreciation.